Semax vs Selank: Nootropic Peptides for Brain Performance

How They Work

Semax and selank are both synthetic peptides developed in Russia during the 1980s and 1990s. Both are administered as intranasal drops. Both cross the blood-brain barrier to act directly on the central nervous system. But their targets, effects, and downstream neurochemistry are fundamentally different. One is a stimulating cognitive enhancer. The other is a calming anxiolytic. Understanding this distinction is the key to understanding when and why each one is used.

Semax is a synthetic fragment of adrenocorticotropic hormone (ACTH), specifically the amino acid sequence 4-10 with a stabilized C-terminus (Pro-Gly-Pro) added to resist enzymatic degradation. ACTH is a pituitary hormone best known for stimulating the adrenal glands. But the 4-10 fragment that forms semax's core does not activate adrenal function. Instead, it acts on the brain. Semax's primary mechanism is the upregulation of brain-derived neurotrophic factor (BDNF), a protein essential for neuronal survival, growth, and synaptic plasticity (PMID: 16027831). BDNF is sometimes called "fertilizer for the brain" because it supports the formation of new neural connections and strengthens existing ones. Higher BDNF levels are associated with improved learning, memory consolidation, and cognitive flexibility. Lower BDNF levels are linked to depression, cognitive decline, and neurodegenerative disease. Semax also modulates dopamine and serotonin systems in the brain, contributing to its noticeable effects on focus, motivation, and mental energy (PMID: 16027831).

In Russia, semax has been approved since the late 1990s as a prescription medication. It is used clinically for stroke recovery, cognitive impairment, peptic ulcers, and optic nerve disorders. The stroke application is particularly notable. Russian neurologists administer semax intranasally to stroke patients to limit ischemic brain damage and promote recovery, leveraging its BDNF-elevating and neuroprotective properties. The approved formulation is a 0.1% nasal solution, though a more concentrated 1% version (sometimes called N-Acetyl Semax or Adamax) exists for more severe neurological conditions.

Selank takes a completely different approach. It is a synthetic analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced by cleavage of immunoglobulin G in the spleen. Tuftsin plays a role in innate immunity and has mild neuromodulatory properties. Russian researchers at the Institute of Molecular Genetics extended tuftsin by adding a stabilizing tripeptide sequence (Pro-Gly-Pro, the same stabilizer used in semax) to create a compound with enhanced central nervous system activity and resistance to breakdown. The result was selank, a heptapeptide with pronounced anxiolytic effects.

Selank's primary mechanism is modulation of the GABAergic system. GABA (gamma-aminobutyric acid) is the brain's main inhibitory neurotransmitter. It is the target of benzodiazepines like Valium and Xanax. Selank influences GABA receptor function and increases the expression of GABA-related genes in the hippocampus, producing an anti-anxiety effect without the sedation, cognitive impairment, or addiction risk associated with benzodiazepines (PMID: 18726017). Selank also modulates enkephalins, endogenous opioid peptides involved in mood regulation and stress response. This dual action on GABA and enkephalin systems gives selank its characteristic effect: reduced anxiety with preserved (and sometimes enhanced) mental clarity.

Both peptides share the Pro-Gly-Pro C-terminal extension, giving them similar metabolic stability and intranasal bioavailability. Both increase BDNF, though through different pathways and with different downstream effects. And both were developed at Russian academic institutions and went through the Russian regulatory approval process. But their neurological signatures are opposite. Semax activates and sharpens. Selank calms and stabilizes. This makes them complementary rather than competing.

What the Research Shows

The published research on semax and selank is concentrated in Russian-language journals and government research programs. Western clinical trials are limited. However, the pharmacological data and Russian clinical experience provide a meaningful evidence base.

Semax: BDNF elevation and dopaminergic activation. The foundational pharmacology study was published by Eremin et al. in the Bulletin of Experimental Biology and Medicine in 2005 (PMID: 16027831). This study demonstrated that semax activates both dopaminergic and serotoninergic systems in the rat brain. Specifically, semax increased dopamine metabolite levels in the striatum and frontal cortex, regions associated with executive function, motivation, and working memory. Serotonin metabolite levels also increased in the hippocampus. These neurochemical changes are consistent with the cognitive enhancement and mood-brightening effects reported by users. Separately, studies have shown that semax significantly upregulates BDNF and its receptor TrkB in the hippocampus and cerebral cortex, with BDNF mRNA increases of 1.5 to 3-fold depending on dosing and brain region. This BDNF upregulation appears within hours of administration and persists for several hours after a single dose.

Semax in stroke recovery. Russian clinical data on semax in ischemic stroke is substantial, though most studies are published in Russian journals and not indexed in Western databases. The available translated literature reports that intranasal semax administered within the first 6-12 hours of an ischemic stroke reduces infarct volume, improves neurological outcomes, and accelerates recovery of motor and cognitive function. The proposed mechanism is dual: BDNF-mediated neuroprotection (supporting neuronal survival in the penumbra, the at-risk tissue surrounding the core infarct) and anti-inflammatory effects that reduce secondary damage. Semax has been included in Russian national clinical guidelines for acute ischemic stroke treatment.

Semax and gene expression. Beyond its acute neurotransmitter effects, semax appears to influence gene expression in the brain at a broader level. Research has identified changes in the expression of genes related to neurotrophic signaling, immune modulation, and vascular function following semax administration. One study using microarray analysis found that semax altered the expression of over 100 genes in rat brain tissue after focal ischemia, with the majority of changes occurring in pathways related to neuroprotection and inflammation. This gene-level data suggests that semax's effects extend beyond simple neurotransmitter modulation into longer-term structural and functional brain support.

Selank: Anxiolytic activity without sedation. The key study was published by Zozulya et al. in the Bulletin of Experimental Biology and Medicine in 2008 (PMID: 18726017). This paper characterized selank as an anxiolytic peptide with activity comparable to benzodiazepines in animal models of anxiety, but without the sedative, amnestic, or dependence-producing effects. In the elevated plus-maze test, a standard anxiety model in rodents, selank significantly increased time spent in open arms (indicating reduced anxiety) without impairing locomotor activity or coordination. This dissociation between anxiolytic effect and sedation is the critical finding. Benzodiazepines reduce anxiety but also impair memory, slow reaction time, and carry significant addiction risk. Selank appears to reduce anxiety while preserving or even enhancing cognitive function.

Selank: Immunomodulatory effects. Because selank is derived from tuftsin, an immunoactive peptide, it retains some immunomodulatory properties. Research has shown that selank influences the expression of genes involved in immune function, particularly interleukin signaling. Specifically, selank has been shown to modulate the balance between pro-inflammatory and anti-inflammatory cytokines, shifting the profile toward a more regulated immune state. In Russia, selank has been studied as an adjunct treatment for conditions involving both anxiety and immune dysfunction, such as generalized anxiety disorder with concurrent immunosuppression. This dual anxiolytic-immunomodulatory profile is unique among anti-anxiety compounds. No benzodiazepine, SSRI, or buspirone provides meaningful immune modulation alongside its psychiatric effects.

BDNF modulation by both peptides. Both semax and selank increase BDNF, but the functional significance differs. Semax's BDNF elevation occurs in the context of increased dopaminergic tone, producing a stimulatory, pro-cognitive effect. The brain is more alert, more plastic, more responsive to learning. Selank's BDNF modulation occurs in the context of enhanced GABAergic tone, producing a stabilizing effect. The brain is calmer, more resilient to stress, but still capable of forming new connections. Same neurotrophic factor, different neurochemical environments, different functional outcomes.

Limitations of the evidence. Neither peptide has undergone Phase 3 clinical trials by Western regulatory standards. The Russian approval process, while rigorous within its own framework, does not map directly onto FDA requirements. Most available studies are preclinical (animal models) or small-scale clinical trials published in Russian. The pharmacological mechanisms are well-characterized. The long-term outcome data in large, diverse human populations is not. Western researchers interested in these peptides face a language barrier and a regulatory gap. The science is credible. The evidence base, by Western standards, is still developing.

Side Effects and Tolerability

Both semax and selank are remarkably well-tolerated. Their side effect profiles are mild compared to conventional pharmaceuticals that target similar systems. This tolerability, combined with the intranasal route of administration, is a major reason for their popularity in the nootropics community.

Semax side effects. The most commonly reported effects are mild and transient. Some users experience a slight burning or irritation in the nasal passages immediately after administration. This typically resolves within a few minutes. A small percentage of users report mild headache, particularly during the first few days of use. Because semax activates dopaminergic pathways, there is a theoretical potential for overstimulation in sensitive individuals. This can manifest as restlessness, mild anxiety, or difficulty sleeping if semax is taken too late in the day. These effects are dose-dependent and generally manageable by adjusting timing or dosage.

Semax does not appear to affect adrenal function despite being derived from an ACTH fragment. The 4-10 segment of ACTH does not bind the melanocortin-2 receptor (MC2R) responsible for cortisol production. This means semax should not raise cortisol levels or cause adrenal-related side effects. This has been confirmed in pharmacological studies showing no significant changes in cortisol, aldosterone, or other adrenal hormones following semax administration.

Selank side effects. Selank has an even milder side effect profile. The most common report is transient nasal irritation. Unlike benzodiazepines, selank does not cause drowsiness, motor impairment, or cognitive dulling. Unlike SSRIs, it does not cause sexual dysfunction, weight gain, or emotional blunting. Selank has not been associated with physical dependence or withdrawal symptoms in any published research. In the Zozulya et al. study (PMID: 18726017), selank demonstrated anxiolytic activity without the characteristic benzodiazepine side effect signature of sedation, amnesia, and dependency. This is the core safety advantage. An anti-anxiety compound that does not sedate, impair memory, or create dependency addresses the primary limitations of the most widely prescribed anxiety medications.

Drug interactions. Neither peptide has been extensively studied for drug interactions in Western clinical settings. However, semax's dopaminergic activity suggests caution when combining it with stimulant medications (amphetamines, methylphenidate) or MAO inhibitors. Selank's GABAergic activity suggests caution when combining it with benzodiazepines, alcohol, or other CNS depressants, as additive effects are possible even if selank itself is not sedating. Anyone taking prescription medications should consult a physician before adding either peptide.

Neither peptide is FDA-approved. Semax and selank are classified as research peptides in the United States and most Western countries. They are approved prescription medications in Russia and some former Soviet states. In the US, they are available from research peptide suppliers but are not regulated as pharmaceuticals. This means manufacturing standards, purity, and potency vary by source. Third-party certificates of analysis from independent testing labs are the minimum quality assurance step. Pharmaceutical-grade product from reputable suppliers is essential for both safety and effectiveness.

Cost, Access, and Practical Considerations

Both semax and selank are administered as intranasal drops, which is a significant practical advantage. No injections. No reconstitution with bacteriostatic water. No syringes. The intranasal route provides rapid delivery to the brain via the olfactory mucosa, bypassing the blood-brain barrier more efficiently than oral or subcutaneous administration for peptides of this size.

Typical pricing. Both peptides are similarly priced. Research-grade semax and selank typically cost $30-60 per vial from reputable US-based peptide suppliers. A single vial generally provides 2-4 weeks of use at standard dosing. This makes them relatively affordable compared to many prescription nootropics or anxiolytics, though cost can add up over months of continuous use. Enhanced versions (N-Acetyl Semax Amidate, N-Acetyl Selank Amidate) cost more but are reported to have longer duration and stronger effects due to improved metabolic stability.

Dosing protocols. Semax is typically dosed at 200-600 mcg intranasally, 1-2 times per day. Most users administer it in the morning or early afternoon to avoid any interference with sleep. The onset of effects is usually within 15-30 minutes, with a duration of 4-6 hours for the standard version. Selank is typically dosed at 250-500 mcg intranasally, 1-3 times per day. Because it is calming rather than stimulating, timing is more flexible. Some users take it in the evening or before high-stress situations. Effects onset within 10-20 minutes.

Storage and handling. Both peptides in nasal spray form should be stored refrigerated at 2-8 degrees Celsius. Some formulations can tolerate brief periods at room temperature, but refrigeration preserves potency. Shelf life once opened is typically 30-60 days when refrigerated properly. Keep sprays away from heat, direct sunlight, and contamination.

Cycling. There is no strong consensus on whether cycling is necessary for either peptide. Russian clinical protocols for semax typically involve courses of 10-14 days followed by a break, often structured as 10 days on followed by 10 days off, or 3 weeks on followed by 1 week off. The rationale is to prevent receptor desensitization, though clear evidence of tolerance development at standard doses has not been documented. Some users in the nootropics community use semax continuously for months without reported tolerance or diminished effects. Selank appears to maintain its anxiolytic effect over extended periods without tolerance buildup, which is consistent with its mechanism (GABAergic modulation rather than direct receptor agonism). That said, periodic breaks are a reasonable precaution given the limited long-term data available.

Enhanced variants. Both peptides have modified versions available from research suppliers. N-Acetyl Semax and N-Acetyl Semax Amidate add acetyl and amide groups to the peptide, respectively, increasing resistance to enzymatic breakdown and extending duration of action. Users report that the acetylated version feels stronger and lasts longer per dose. Similarly, N-Acetyl Selank Amidate is reported to have a more pronounced and longer-lasting anxiolytic effect than standard selank. These enhanced variants cost more and have even less published research behind them than the standard versions. They are modifications designed for stability, not fundamentally different compounds.

The stack: semax in the morning, selank in the evening. The most commonly discussed combination protocol uses semax in the morning for cognitive enhancement and focus throughout the workday, then selank in the late afternoon or evening for stress recovery and anxiety management. This pairing leverages the complementary pharmacology: stimulating dopaminergic and BDNF-driven cognitive enhancement during active hours, followed by GABAergic calming and mood stabilization during recovery hours. Some users take both simultaneously and report a state of "focused calm," though this is anecdotal rather than clinically studied. The fact that they work through entirely different receptor systems (melanocortin/dopamine for semax, GABA/enkephalin for selank) supports the safety of concurrent use, though combined human pharmacokinetic data is not available.

Legal status. In Russia, both are approved prescription medications available in pharmacies. In the United States, both are legal to purchase as research peptides but are not approved for human therapeutic use. They are not scheduled or controlled substances. The regulatory gray area means quality control depends entirely on the supplier. This is a practical consideration that should not be ignored.

The Bottom Line

Semax and selank are not competitors. They are complementary nootropic peptides that target opposite ends of the cognitive spectrum. Semax sharpens, stimulates, and enhances focus through BDNF elevation and dopaminergic activation. Selank calms, stabilizes, and reduces anxiety through GABA modulation and enkephalin release. Choosing between them depends entirely on what problem you are trying to solve.

If cognitive performance, focus, learning capacity, and neuroprotection are the priority, semax is the more appropriate choice. Its BDNF-elevating properties and dopaminergic activation make it a well-characterized nootropic with a specific mechanism for enhancing mental clarity and processing speed. Russian clinical use in stroke recovery speaks to its neuroprotective potency.

If anxiety reduction, stress resilience, and mood stabilization are the priority, selank is the better fit. Its benzodiazepine-comparable anxiolytic activity without sedation, cognitive impairment, or addiction risk addresses the central limitation of conventional anti-anxiety medications. For someone who needs to stay sharp while managing anxiety, selank offers a profile that most pharmaceuticals cannot match.

Many users do not choose between them at all. The morning semax, evening selank protocol is one of the most discussed peptide stacks in the nootropics community. The pharmacological rationale is sound. Different receptor targets, different neurochemical effects, complementary functional outcomes. But this combination has not been formally studied in clinical trials, and the evidence supporting it is mechanistic and anecdotal rather than outcomes-based.

Neither peptide is FDA-approved for any therapeutic indication in the United States. Both are approved in Russia. The published research establishes clear pharmacological mechanisms and favorable safety profiles in the short to medium term. Long-term data from large Western clinical trials does not exist. The mechanistic science is credible. The clinical evidence, by Western regulatory standards, remains incomplete. Anyone considering either peptide should work with a physician familiar with peptide therapy and should source product from suppliers that provide independent third-party testing verification.